Published in Ther Clin Risk Manag on June 13, 2014
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Natural history of venous thromboembolism. Circulation (2003) 3.67
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Laboratory assessment of new anticoagulants. Clin Chem Lab Med (2011) 1.99
Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med (2005) 1.90
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost (2008) 1.55
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol (2003) 1.41
Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J (1980) 1.27
Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb (2009) 1.16
Cancer-associated thrombosis. Crit Rev Oncol Hematol (2007) 1.15
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost (2012) 1.10
Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost (2009) 1.02
Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program (2010) 1.01
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost (2010) 1.00
Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res (2010) 0.95
Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res (2003) 0.95
New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis (2010) 0.90
Newer anticoagulants in 2009. J Thromb Thrombolysis (2010) 0.90
Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer (2010) 0.88
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res (2011) 0.88
Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des (2005) 0.88
Upper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registry. Exp Oncol (2006) 0.87
Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost (2007) 0.82
Occult cancer in patients with bilateral deep-vein thrombosis. Lancet (1997) 0.80
Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res (2011) 0.79
Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer (2006) 0.78
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag (2008) 0.78
Emerging anticoagulants. Expert Opin Emerg Drugs (2011) 0.76